AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31142269 — intervention group
Group type: EXPERIMENTAL
Intervention: SCCmec types
Number of subjects: 598
Study 31142269 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA isolates carrying PVL genes
Number of subjects: 598
Study 31142269 — intervention group
Group type: EXPERIMENTAL
Intervention: BHS carriers
Number of subjects: 598
Study 31142269 — intervention group
Group type: EXPERIMENTAL
Intervention: BHS susceptibility
Number of subjects: 598
Study 29501977 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab with standard epirubicin, cisplatin, capecitabine (ECX) chemotherapy
Number of subjects: 160
Study 29501977 — intervention group
Group type: COMPARATOR
Intervention: Standard epirubicin, cisplatin, capecitabine (ECX) chemotherapy without panitumumab
Number of subjects: 160
Study 26971236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg
Number of subjects: 201
Study 26971236 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300 mg
Number of subjects: 201
Study 23759131 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal stability ball exercise programme (12 weeks, 3 sessions per week, 25-30 minutes each session)
Number of subjects: 89
Study 23759131 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 89
Study 22950512 — intervention group
Group type: EXPERIMENTAL
Intervention: P. falciparum infection
Number of subjects: 2400
Study 22950512 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia
Number of subjects: 2400
Study 22950512 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for P. falciparum infection
Number of subjects: 2400
Study 22950512 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for anaemia
Number of subjects: 2400
Study 22950512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and educational performance
Number of subjects: 2400
Study 19430064 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon gel sheeting applied to nares (Group 2, n=92)
Number of subjects: 179
Study 19430064 — intervention group
Group type: COMPARATOR
Intervention: No silicon gel applied to nares (Group 1, n=87)
Number of subjects: 179
Study 18555936 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 100 mg (test formulation)
Number of subjects: 24
Study 18555936 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine 100 mg (reference formulation)
Number of subjects: 24
Study 16055570 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of vaginal misoprostol, given 3-4 hours preoperatively
Number of subjects: 84
Study 16055570 — intervention group
Group type: COMPARATOR
Intervention: Overnight laminaria
Number of subjects: 84
Study 16055570 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 12120699 — intervention group
Group type: EXPERIMENTAL
Intervention: MS patients
Number of subjects: 51
Study 12120699 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 10321112 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10985
Study 10321112 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (diuretics or beta-blockers)
Number of subjects: 10985
Study 8727240 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 29
Study 8727240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1748257 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 471
Study 1748257 — intervention group
Group type: COMPARATOR
Intervention: Diet therapy
Number of subjects: 471
Study 1748257 — intervention group
Group type: COMPARATOR
Intervention: Diet therapy in obese subjects
Number of subjects: 471
Study 7201759 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of undiluted erythrocytes
Number of subjects: 0
Study 7201759 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilution of packed erythrocytes with at least 100 ml of normal saline
Number of subjects: 0
Study 7201759 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion flow rates for packed red blood cells
Number of subjects: 0
Study 7201759 — intervention group
Group type: EXPERIMENTAL
Intervention: External bag pressure and transfusion apparatus
Number of subjects: 0
Study 31200671 — intervention group
Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention in Uganda
Number of subjects: 0
Study 31200671 — intervention group
Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention in Colombia
Number of subjects: 0
Study 31200671 — intervention group
Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention in Bosnia-Herzegovina
Number of subjects: 0
Study 31200671 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer Support intervention in Uganda
Number of subjects: 0
Study 31200671 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer Support intervention in Colombia
Number of subjects: 0
Study 31200671 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer Support intervention in Bosnia-Herzegovina
Number of subjects: 0
Study 31200671 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Involvement intervention in Uganda
Number of subjects: 0
Study 31200671 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Involvement intervention in Colombia
Number of subjects: 0
Study 31200671 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Involvement intervention in Bosnia-Herzegovina
Number of subjects: 0
Study 27387376 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagram generation
Number of subjects: 0
Study 27387376 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 0
Study 27387376 — intervention group
Group type: COMPARATOR
Intervention: Reading (control)
Number of subjects: 0
Study 26170351 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 0 mg
Number of subjects: 120
Study 24357936 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2190915 10 mg
Number of subjects: 19
Study 24357936 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2190915 50 mg
Number of subjects: 19
Study 24357936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 20562122 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile telephone-based interactive asthma self-care system
Number of subjects: 89
Study 19620846 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 100-mg capsule BID
Number of subjects: 19
Study 19620846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 19620846 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 19
Study 19620846 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil and Placebo
Number of subjects: 19
Study 16505497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 19
Study 16505497 — intervention group
Group type: COMPARATOR
Intervention: Glipizide 10 mg
Number of subjects: 19
Study 15312219 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus definition for ARF developed
Number of subjects: 0
Study 15312219 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for future investigations
Number of subjects: 0
Study 11331721 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine secretin
Number of subjects: 64
Study 11331721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 9118764 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for special shoes
Number of subjects: 352
Study 9118764 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe length
Number of subjects: 352
Study 9118764 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe width
Number of subjects: 352
Study 9118764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bought shoes in the past 6 months
Number of subjects: 352
Study 8320055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1 g/day for 28 days)
Number of subjects: 32
Study 8320055 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (1 g/day for 28 days)
Number of subjects: 32
Study 8320055 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol and ascorbic acid (1 g/day for 28 days each)
Number of subjects: 32
Study 8320055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3090049 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 42
Study 3090049 — intervention group
Group type: COMPARATOR
Intervention: Manipulative reduction and plaster
Number of subjects: 42
Study 29203268 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light flexible cystoscopy
Number of subjects: 304
Study 29203268 — intervention group
Group type: COMPARATOR
Intervention: White light flexible cystoscopy
Number of subjects: 304
Study 27824768 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive gestational weight gain
Number of subjects: 841
Study 25663279 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood pleurodesis (ABP)
Number of subjects: 48
Study 25663279 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline pleurodesis
Number of subjects: 48
Study 23480441 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Magill forceps
Number of subjects: 150
Study 23480441 — intervention group
Group type: COMPARATOR
Intervention: Standard Magill forceps
Number of subjects: 150
Study 21181560 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-intervention (8-minute video depicting clinician expert and patients discussing challenges in seeking treatment for sickle cell pain)
Number of subjects: 276
Study 21181560 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-intervention
Number of subjects: 276
Study 19720914 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra boost dose of 16 Gy
Number of subjects: 1616
Study 19720914 — intervention group
Group type: COMPARATOR
Intervention: Margin status (negative, close, positive)
Number of subjects: 1616
Study 19720914 — intervention group
Group type: COMPARATOR
Intervention: Age younger than 50 years
Number of subjects: 1616
Study 19720914 — intervention group
Group type: COMPARATOR
Intervention: High-grade invasive ductal carcinoma
Number of subjects: 1616
Study 17315077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019 (high dose: 5 x 10^9 CFU/day)
Number of subjects: 80
Study 17315077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019 (medium dose: 1.0 x 10^9 CFU/day)
Number of subjects: 80
Study 17315077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019 (low dose: 6.5 x 10^7 CFU/day)
Number of subjects: 80
Study 17315077 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no probiotic supplement)
Number of subjects: 80
Study 15285601 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefactual reasoning
Number of subjects: 0
Study 15285601 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterfactual reasoning
Number of subjects: 0
Study 11690570 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplements
Number of subjects: 145
Study 11690570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 11690570 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of at least 1000 mg per day
Number of subjects: 145
Study 11690570 — intervention group
Group type: COMPARATOR
Intervention: Calcium intake of less than 1000 mg per day
Number of subjects: 145
Study 9399717 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal daily physical activities (Group 1, 54 patients)
Number of subjects: 106
Study 9399717 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization during recording (Group 2, 52 patients)
Number of subjects: 106
Study 9399717 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 106
Study 8548234 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant concentration measured before and after exercise
Number of subjects: 29
Study 8548234 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria measured before and after exercise
Number of subjects: 29
Study 8548234 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between antioxidant concentration and microalbuminuria
Number of subjects: 29
Study 8548234 — intervention group
Group type: COMPARATOR
Intervention: Total antioxidant concentration at rest
Number of subjects: 29
Study 2502004 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of 344 mumol of zinc
Number of subjects: 0
Study 2502004 — intervention group
Group type: COMPARATOR
Intervention: 421 mumol of Fe alone
Number of subjects: 0
Study 2502004 — intervention group
Group type: EXPERIMENTAL
Intervention: 421 mumol of Zn
Number of subjects: 0
Study 2502004 — intervention group
Group type: EXPERIMENTAL
Intervention: 1048 mumol of Zn
Number of subjects: 0
Study 320112 — intervention group
Group type: EXPERIMENTAL
Intervention: Duogastrone (50 mg capsules, 200 mg daily for 12 weeks)
Number of subjects: 40
Study 320112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31494973 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond alexandrite laser treatment (3 sessions at 4-week intervals)
Number of subjects: 29
Study 31494973 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond alexandrite laser treatment (5 sessions at 4-week intervals)
Number of subjects: 29
Study 31494973 — intervention group
Group type: COMPARATOR
Intervention: Triple combination cream (TCC) daily for at least 8 weeks
Number of subjects: 29
Study 31494973 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond alexandrite laser treatment (3 sessions)
Number of subjects: 29
Study 31494973 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond alexandrite laser treatment (5 sessions)
Number of subjects: 29
Study 31277968 — intervention group
Group type: EXPERIMENTAL
Intervention: SC+ACT‐ED
Number of subjects: 53
Study 28486907 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin (15 mg twice a day)
Number of subjects: 60
Study 28486907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice a day)
Number of subjects: 60
Study 28486907 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin
Number of subjects: 60
Study 28486907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25367014 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) training scenario for social eating situations
Number of subjects: 37
Study 26218762 — intervention group
Group type: EXPERIMENTAL
Intervention: HF10 therapy
Number of subjects: 198
Study 26218762 — intervention group
Group type: COMPARATOR
Intervention: Traditional low-frequency SCS
Number of subjects: 198
Study 23314000 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Family Therapy (RFT)
Number of subjects: 50
Study 23314000 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 50
Study 20439790 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 136
Study 20439790 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (institutional care)
Number of subjects: 136
Study 19029421 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (androgen deprivation)
Number of subjects: 286
Study 19029421 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemohormonal group (ketoconazole and doxorubicin alternating with vinblastine and estramustine)
Number of subjects: 286
Study 16774150 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin (0.3 mg)
Number of subjects: 36
Study 16774150 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin (5.0 mg)
Number of subjects: 36
Study 16774150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12966323 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 150
Study 12966323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 10963173 — intervention group
Group type: EXPERIMENTAL
Intervention: Insole with a lateral wedge (group I)
Number of subjects: 30
Study 10963173 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment without an insole (group II)
Number of subjects: 30
Study 9205160 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-ketoglutarate (28 g added to blood cardioplegia)
Number of subjects: 24
Study 7959497 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (1,000 mg daily for six days)
Number of subjects: 20
Study 7959497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2455180 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine treatment (150 micrograms t.i.d. for 2 weeks)
Number of subjects: 24
Study 2455180 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine treatment (0.36 ± 0.07 mg daily for 1 month)
Number of subjects: 24
Study 2455180 — intervention group
Group type: COMPARATOR
Intervention: Propranolol treatment (160 mg daily for 1 month)
Number of subjects: 24
Study 2455180 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine withdrawal
Number of subjects: 24
Study 2455180 — intervention group
Group type: COMPARATOR
Intervention: Propranolol withdrawal
Number of subjects: 24
Study 31958274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue numeric rating scale (NRS)
Number of subjects: 0
Study 31958274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue NRS
Number of subjects: 0
Study 29804059 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (60 mg/kg/day of DHA)
Number of subjects: 72
Study 29804059 — intervention group
Group type: COMPARATOR
Intervention: Control emulsion
Number of subjects: 72
Study 27422158 — intervention group
Group type: EXPERIMENTAL
Intervention: two-desk sit-to-stand workstations
Number of subjects: 18
Study 27422158 — intervention group
Group type: EXPERIMENTAL
Intervention: traditional sit-to-stand workstations
Number of subjects: 18
Study 27422158 — intervention group
Group type: COMPARATOR
Intervention: control group (no changes during the study)
Number of subjects: 18
Study 24047757 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lutein/d (n=48)
Number of subjects: 144
Study 24047757 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lutein/d + 20 mg lycopene/d (n=48)
Number of subjects: 144
Study 24047757 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=48)
Number of subjects: 144
Study 23868654 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal local therapy (LipoSaliva®, LipoNasal®, and Tears Again®) for 2 months
Number of subjects: 73
Study 20642248 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) at 1 of 3 dose levels (5, 10, or 20 microg/b)
Number of subjects: 0
Study 20642248 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal system (TDS)
Number of subjects: 0
Study 20642248 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS)
Number of subjects: 0
Study 18828707 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective cerebral hypothermia methods (e.g., surface cooling, intranasal selective hypothermia, transarterial or transvenous endovascular cooling, extraluminal vascular cooling, epidural cerebral cooling)
Number of subjects: 0
Study 16627891 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and 2.4 g AA/kg/d
Number of subjects: 32
Study 16627891 — intervention group
Group type: COMPARATOR
Intervention: Solely glucose
Number of subjects: 32
Study 12841468 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer-administered assessment (participants' responses recorded by interviewer)
Number of subjects: 80
Study 12841468 — intervention group
Group type: COMPARATOR
Intervention: Self-answer method (participants record their own responses)
Number of subjects: 80
Study 11015099 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple ITA grafts (all-ITA)
Number of subjects: 162
Study 11015099 — intervention group
Group type: COMPARATOR
Intervention: ITA plus SVG (control group)
Number of subjects: 162
Study 8843534 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of melatonin
Number of subjects: 12
Study 8843534 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of melatonin
Number of subjects: 12
Study 8843534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8070301 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO criteria for IGT
Number of subjects: 128
Study 3311118 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine bronchial challenge using the DeVilbiss 646 nebulizer
Number of subjects: 18
Study 3311118 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine bronchial challenge using the DeVilbiss 646 nebulizer
Number of subjects: 18
Study 29028377 — intervention group
Group type: COMPARATOR
Intervention: Topical 5% minoxidil (1 ml twice daily)
Number of subjects: 60
Study 29028377 — intervention group
Group type: COMPARATOR
Intervention: Local electrodynamic microneedle treatments
Number of subjects: 60
Study 29028377 — intervention group
Group type: EXPERIMENTAL
Intervention: Local electrodynamic microneedle treatments plus topical 5% minoxidil (2 ml during each microneedle treatment)
Number of subjects: 60
Study 30210790 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized version of the Louvain algorithm with edge and layer weights
Number of subjects: 0
Study 30210790 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized version of the Louvain algorithm
Number of subjects: 0
Study 27025868 — intervention group
Group type: EXPERIMENTAL
Intervention: MyKnee(®) patient-specific instrumentation (PSI)
Number of subjects: 0
Study 27025868 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 0
Study 27025868 — intervention group
Group type: EXPERIMENTAL
Intervention: MyKnee(®) PSI
Number of subjects: 0
Study 23692645 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypertension
Number of subjects: 240
Study 23692645 — intervention group
Group type: COMPARATOR
Intervention: No induced hypertension
Number of subjects: 240
Study 22876692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushenhuoxue Granules (BSHXG)
Number of subjects: 120
Study 22876692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20819623 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone (50 microg salmeterol and 500 microg fluticasone twice daily)
Number of subjects: 122